[go: up one dir, main page]

MX2013015280A - Inhibidores de fosfodiesterasas por via transvaginal para el tratamiento de la infertabilidad. - Google Patents

Inhibidores de fosfodiesterasas por via transvaginal para el tratamiento de la infertabilidad.

Info

Publication number
MX2013015280A
MX2013015280A MX2013015280A MX2013015280A MX2013015280A MX 2013015280 A MX2013015280 A MX 2013015280A MX 2013015280 A MX2013015280 A MX 2013015280A MX 2013015280 A MX2013015280 A MX 2013015280A MX 2013015280 A MX2013015280 A MX 2013015280A
Authority
MX
Mexico
Prior art keywords
treatment
transvaginal
inhibitors
infertability
phosphodesterase
Prior art date
Application number
MX2013015280A
Other languages
English (en)
Other versions
MX365773B (es
Inventor
Maria Carmen Pardina Palleja
Miguel Angel Vaz-Romero Uña
Original Assignee
Maria Carmen Pardina Palleja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Carmen Pardina Palleja filed Critical Maria Carmen Pardina Palleja
Publication of MX2013015280A publication Critical patent/MX2013015280A/es
Publication of MX365773B publication Critical patent/MX365773B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una nueva aplicación de los inhibidores de fosfodiesterasas para el tratamiento de la infertilidad de parejas, que constituye una alternativa eficaz a las técnicas invasivas de reproducción asistida, como la inseminación artificial conyugal, y que consiste en la administración transvaginal de un inhibidor de fosfodiesterasas inmediatamente antes y/o después de realizar el coito. También se refiere a formas farmacéuticas aptas para la administración intravaginal de inhibidores de fosfodiesterasas.
MX2013015280A 2011-06-23 2012-06-20 Inhibidores de fosfodiesterasas por via transvaginal para el tratamiento de la infertabilidad. MX365773B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201131059A ES2395801B1 (es) 2011-06-23 2011-06-23 "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
PCT/ES2012/070453 WO2012175775A1 (es) 2011-06-23 2012-06-20 Inhibidores de fosfodiesterasas por vía transvaginal para el tratamiento de la infertilidad

Publications (2)

Publication Number Publication Date
MX2013015280A true MX2013015280A (es) 2014-08-01
MX365773B MX365773B (es) 2019-06-10

Family

ID=46603994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015280A MX365773B (es) 2011-06-23 2012-06-20 Inhibidores de fosfodiesterasas por via transvaginal para el tratamiento de la infertabilidad.

Country Status (21)

Country Link
US (2) US9220679B2 (es)
EP (1) EP2724716B1 (es)
JP (2) JP6373755B2 (es)
KR (1) KR101948355B1 (es)
AU (1) AU2012273879B2 (es)
CA (1) CA2846498C (es)
CY (1) CY1119860T1 (es)
DK (1) DK2724716T3 (es)
ES (2) ES2395801B1 (es)
HR (1) HRP20180105T1 (es)
HU (1) HUE036489T2 (es)
LT (1) LT2724716T (es)
MX (1) MX365773B (es)
NO (1) NO2724716T3 (es)
PL (1) PL2724716T3 (es)
PT (1) PT2724716T (es)
RS (1) RS56921B1 (es)
RU (1) RU2601913C2 (es)
SI (1) SI2724716T1 (es)
SM (1) SMT201800093T1 (es)
WO (1) WO2012175775A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025048853A (ja) * 2023-09-20 2025-04-03 ソフトバンクグループ株式会社 システム

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US3422107A (en) 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
JPS5229318B2 (es) 1972-03-30 1977-08-01
DE2413935A1 (de) 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
JPS52156913A (en) * 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
ZA807267B (en) 1979-11-26 1981-11-25 Sterling Drug Inc 5-(pyridinyl)-2(1h)-pyridinones,useful as cardiotonic agents and their preparation
GB8607570D0 (en) * 1986-03-26 1986-04-30 Euro Celtique Sa Vaginal pharmaceutical preparation
JPH0347134A (ja) * 1989-03-08 1991-02-28 Hoechst Japan Ltd ヒドロゲル製剤およびキセロゲル製剤の製造法
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
JP2001520999A (ja) * 1997-10-28 2001-11-06 アシビ， エルエルシー 女性の性的機能不全の処置
DE19801438A1 (de) * 1998-01-16 1999-07-29 Haemopep Pharma Gmbh Verwendung von spezifischen Phosphodiesterase-Inhibitoren zur Erhöhung der Spermienmotilität
WO1999062533A1 (en) * 1998-06-04 1999-12-09 Jedco Products, Llc Preparation for topical application to the male sexual organ
CA2409592A1 (en) * 2000-05-22 2001-11-29 Illana Gozes Pharmceutical compositions comprising vip-related peptides for the treatment of sexual disorders
WO2002083102A1 (en) * 2001-02-23 2002-10-24 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
AU2003216213B2 (en) * 2002-02-07 2008-10-02 The Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides
EP1473034A1 (en) * 2003-03-17 2004-11-03 Lagow GmbH Use of an inhibitor of the phosphodiesterase-4-enzyme (PDE4) alone or in combination with relaxin and derivatives thereof for the manufacture of a medicament to promote decidualization of endometrial cells and to increase fertility
WO2004087211A2 (en) * 2003-04-01 2004-10-14 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
CA2537080A1 (en) * 2003-08-21 2005-03-31 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
ES2245609B1 (es) 2004-06-18 2007-08-16 Universidad De Barcelona Nuevo agente terapeutico para el tratamiento de la infertilidad y/o subfertilidad masculina en mamiferos.
CN103145842A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
US8980840B2 (en) * 2009-01-13 2015-03-17 Schepens Eye Research Institute Therapeutic modulation of vaginal epithelium boundary lubrication

Also Published As

Publication number Publication date
KR20140043927A (ko) 2014-04-11
SMT201800093T1 (it) 2018-03-08
CA2846498C (en) 2019-01-15
KR101948355B1 (ko) 2019-02-14
EP2724716B1 (en) 2017-11-22
HUE036489T2 (hu) 2018-07-30
RS56921B1 (sr) 2018-05-31
NO2724716T3 (es) 2018-04-21
AU2012273879B2 (en) 2017-04-13
JP2017075185A (ja) 2017-04-20
US9220679B2 (en) 2015-12-29
HRP20180105T1 (hr) 2018-03-23
US20140194448A1 (en) 2014-07-10
EP2724716A1 (en) 2014-04-30
ES2656204T3 (es) 2018-02-26
JP6347858B2 (ja) 2018-06-27
BR112013032855A2 (pt) 2017-01-24
CY1119860T1 (el) 2018-06-27
PL2724716T3 (pl) 2018-04-30
ES2395801A1 (es) 2013-02-15
AU2012273879A1 (en) 2014-02-06
PT2724716T (pt) 2017-12-26
RU2601913C2 (ru) 2016-11-10
JP2014518221A (ja) 2014-07-28
DK2724716T3 (en) 2018-02-12
WO2012175775A1 (es) 2012-12-27
MX365773B (es) 2019-06-10
SI2724716T1 (en) 2018-03-30
ES2395801B1 (es) 2014-06-06
RU2014101761A (ru) 2015-08-20
CA2846498A1 (en) 2012-12-27
JP6373755B2 (ja) 2018-08-15
US20160074407A1 (en) 2016-03-17
LT2724716T (lt) 2018-02-26

Similar Documents

Publication Publication Date Title
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
UY32640A (es) Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
CL2018000523A1 (es) Método para la inhibición de la absorción de lípidos y/o la promoción de excreción de lípidos usando d-psicosa
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
NI201200029A (es) Compuestos y composiciones como inhibidores de cinasa de proteína
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
CL2012003110A1 (es) Compuestos derivados de n-[(2-oxo-1,2-dihidro-3-piridinil)metil]-1h-indol-4-carboxamida, inhibidores de ezh2; composicion farmaceutica que los contiene; utiles en el tratamiento del cancer seleccionado del grupo que consiste de cerebro (gliomas) glioblastomas, leucemias y linfomas, y trastornos mediados por la inhibicion del ezh2.
CR20160200A (es) Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
MX2019001253A (es) Conjugados de proteina-agente activo y metodo para su preparacion.
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
DOP2014000046A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
UY31775A (es) Compuestos heterocíclicos como inhibidores de mek

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: PROKREA BCN, S.L.

FG Grant or registration